12 Best Healthcare Stocks to Buy and Hold for 5 Years

Page 9 of 10

2. Zoetis Inc. (NYSE:ZTS)

Number of Hedge Fund Holders: 75

Zoetis Inc. (NYSE:ZTS), a global leader in animal health, reported solid second-quarter 2025 results with revenue rising 4% year-over-year to $2.5 billion and net income up 15% to $718 million. Growth was driven by an 8% increase in companion animal product sales, led by flagship products such as Simparica Trio for parasite prevention and pain and dermatology treatments, including Rela Solens, Apoquel, and Cytopoint. On the back of these results, ZTS raised its full-year revenue forecast to $9.45–$9.6 billion and guided adjusted earnings per share to between $6.30 and $6.40.

In September, the company announced a major pipeline milestone with a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) for Portela® (relfovetmab). This monoclonal antibody is designed to treat osteoarthritis pain in cats, potentially offering up to three months of relief from a single injection. If approved by the European Commission in Q4 2025, it would become the first long-acting anti-NGF therapy for cats, addressing a widespread but underdiagnosed condition affecting an estimated 40% of the feline population.

Zoetis Inc. (NYSE:ZTS) will provide further updates on its financial and strategic outlook during its third-quarter earnings webcast and conference call scheduled for November 4, 2025, with CEO Kristin Peck and CFO Wetteny Joseph.

Page 9 of 10